黑料不打烊

Global Hemorrhoid Treatment Devices Market Trends and Insights

Rising Prevalence of Hemorrhoidal Disease

Up to 50% of adults older than 50 experience symptomatic hemorrhoids, and growing life expectancy is pushing absolute case numbers higher. China alone is bracing for 1.4 million annual colorectal cancer cases by 2040; national screening rollouts mean more incidental hemorrhoid diagnoses that move quickly to procedural care.^{[3] J. Zheng et al., 鈥淐olorectal Cancer Projections in China,鈥� The Lancet Oncology, thelancet.com} Similar screening acceleration is visible in India, Japan, and South Korea. The clinical community now favors earlier device intervention for Grades II-III to prevent progression, anchoring a long-term tailwind for the hemorrhoid treatment devices market.

Growing Adoption of Minimally Invasive Outpatient Procedures

Payers continue to steer patients away from inpatient excisional surgery toward office or ASC-based ligation. Medicare reimburses rubber band ligation (CPT 46221) at USD 158.85 per facility case in 2026, a level that supports high-volume practice economics. Vizient forecasts a 19% jump in total U.S. outpatient surgery between 2024 and 2034, with gastrointestinal work leading the rise. The convenience of 15-minute visits and same-day discharge aligns with patient preference, accelerating device throughput and revenue.

Technological Advances in Ligation and Energy Devices

Single-use bipolar probes, infrared coagulators, and reloadable clips continue to roll out with superior ergonomics and faster hemostasis. Olympus鈥� 2025 Retentia HemoClip and EZ Clip launches blended reusable and disposable strategies to accommodate divergent hospital budgets. Peer-reviewed trials report postoperative pain scores 30-40% lower with laser hemorrhoidoplasty than with conventional excision, supporting premium pricing and higher adoption of energy-based devices.

Expanding Healthcare Infrastructure in Emerging Economies

India鈥檚 pledge to lift public health spending to 2.5% of GDP by 2025 is translating into new endoscopy suites and subsidized colorectal screening. Similar budgets are visible in Indonesia, Vietnam, and Saudi Arabia. As middle-income hospitals secure financing, they are procuring mid-tier mechanical ligators first, then layering on energy platforms as procedure volumes climb. This gradual technology laddering broadens the total addressable base of the hemorrhoid treatment devices market.

High Cost of Stapling and Laser Systems

Capital outlays above USD 50,000 for a single laser console discourage adoption in resource-constrained hospitals despite clinical benefits. Deferred purchases are common in sub-Saharan Africa and lower-tier Chinese cities where budget committees favor mechanical ligators that cost one-tenth as much. Financing programs and leasing models are emerging, yet payback timelines stretch beyond five years for many facilities, slowing energy platform penetration.

Stringent FDA/CE Regulatory Pathways

Energy-based devices often require De Novo or pre-market approval, adding years and millions in test costs. Signum Surgical鈥檚 BioHealx cleared the FDA鈥檚 De Novo route only in mid-2024 after multiple clinical rounds, illustrating the hurdle for smaller innovators. While necessary for patient safety, these steps delay market entry and compress patent-protected sales windows.

Segment Analysis

By Product Type: Band Ligator Leadership, Laser Momentum

Band ligators owned 41.55% of 2025 revenue, underpinning the mechanical core of the hemorrhoid treatment devices market. High throughput, CPT-linked reimbursement, and a five-minute room turnaround keep demand brisk in physician offices and ASCs. The segment also benefits from infection-control upgrades as manufacturers roll out single-use variants. Laser probes, however, are set for a 9.01% CAGR, driven by compelling randomized evidence of superior pain relief and quicker return to work. Hospitals looking to differentiate colorectal programs are acquiring laser consoles, and private insurers in Germany and Japan now reimburse laser hemorrhoidoplasty, further lifting penetration.

Note: Segment shares of all individual segments available upon report purchase

By Technology Platform: Mechanical Base, Energy Upswing

Mechanical systems generated 53.74% of the hemorrhoid treatment devices market size in 2025 thanks to band ligator ubiquity and their minimal learning curve. Budget-sensitive public hospitals in Latin America and Africa still prioritize these platforms. Energy-based devices are catching up at an 8.92% CAGR, led by bipolar and infrared coagulators that eliminate costly endoscope reprocessing. ASCs in the U.S. often bundle a disposable probe into the procedure fee, easing capital constraints and smoothing the upgrade path for surgeons.

By Hemorrhoid Grade: II Dominant, IV Accelerating

Grade II treatments represented 39.62% of global volume in 2025, reflecting payers鈥� and clinicians鈥� preference for early outpatient management. The hemorrhoid treatment devices market share in Grade IV remains smaller but is expanding at an 8.01% CAGR as tertiary centers adopt Doppler-guided artery ligation and stapled hemorrhoidopexy for complex prolapse. Improved anesthesia protocols and faster discharge policies now allow many Grade IV cases to be scheduled in ASCs instead of inpatient ORs, broadening device demand.

Note: Segment shares of all individual segments available upon report purchase

By Procedure: Rubber Band First, Laser Fastest

Rubber band ligation dominated with 37.76% of 2025 procedures, and its cost advantage guarantees continued leadership. That said, laser therapy is rising on a 9.14% trajectory. Surgeons appreciate the bloodless field and reduced postoperative edema, and patients favor the short recovery window. Doppler-guided artery ligation and stapled hemorrhoidopexy fill more specialized niches, typically reserved for recurrent or circumferential prolapse.

By End User: Hospital Core, ASC Growth Track

Hospitals held 46.51% of 2025 spending, anchored by complex Grade III-IV caseloads and in-house anesthesia teams. Still, the hemorrhoid treatment devices market size captured by ASCs is climbing quickly at 8.33% CAGR as payers shift authorizations toward same-day settings. Physician offices remain the workhorse for single-ligator visits, especially in North America, while home-care use of disposable anoscopes is embryonic but gathering interest from tele-health startups.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America generated 33.43% of 2025 revenue, underpinned by 6,300 Medicare-certified ASCs and clear procedural reimbursement. FDA device-intensive policies continue to influence purchasing, and infection-control rules make single-use ligators standard in many U.S. hospitals. Canada shows similar patterns, though provincial budgets extend capital cycles by one to two years longer than U.S. averages.

Asia-Pacific is the fastest-growing arena at 8.43% CAGR through 2031. China is scaling colorectal screening, and provincial insurance now covers laser hemorrhoidoplasty in several pilot provinces. India鈥檚 private hospital chains are opening dedicated day-surgery wings, equipping them with bipolar and infrared platforms to differentiate from public facilities. Southeast Asian markets such as Indonesia are piggybacking on endoscopy infrastructure funded for gastric cancer programs, creating incremental device demand.

Europe represents a mature but technology-hungry region. Germany and France reimburse energy-based procedures at higher tariffs than mechanical ligation, encouraging steady console refresh cycles every five to seven years. The United Kingdom is channeling National Health Service capital toward infection-risk reduction, pushing single-use devices to the fore. In Southern Europe, lingering budget limits lengthen adoption timelines, though EU-wide infection directives are narrowing the gap.

The Middle East & Africa and South America together account for a modest share but are important long-run contributors. Gulf Cooperation Council hospitals have moved rapidly into Doppler-guided and laser techniques to attract medical tourists, while Brazil and Colombia are expanding public coverage of outpatient ligation. Persistent shortages of colorectal surgeons and capital constraints temper growth, yet tele-endoscopy pilots and private specialty clinics are beginning to unlock latent demand.